JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 24, 2004; DOI: 10.1124/jpet.104.073205


0022-3565/05/3121-199-205$20.00
JPET 312:199-205, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.073205v1
312/1/199    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salama, N. N.
Right arrow Articles by Eddington, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salama, N. N.
Right arrow Articles by Eddington, N. D.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

The Impact of {Delta}G on the Oral Bioavailability of Low Bioavailable Therapeutic Agents

Noha N. Salama, Alessio Fasano, Manjusha Thakar, and Natalie D. Eddington

Pharmacokinetics-Biopharmaceutics Laboratory, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Baltimore, Maryland (N.N.S., N.D.E.); and Division of Pediatric Gastroenterology and Nutrition and Gastrointestinal Section, Center for Vaccine Development, Department of Physiology, School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland (A.F., M.T.)

Low oral bioavailability continues to drive research toward identifying novel approaches to enhance drug delivery. Over the past few years, emphasis on the use of absorption enhancers has been overwhelming despite their major adverse effects. Zonula occludens toxin (Zot) was recently established as a safe and effective absorption enhancer, reversibly opening the tight junctions for hydrophilic markers and hydrophobic drugs across the small intestine and the blood brain barrier. {Delta}G, the biologically active fragment of Zot, was isolated and shown to increase the in vitro transport and in vivo absorption of paracellular markers. The objective of this study was to examine the effect of {Delta}G on the oral bioavailability of low bioavailable therapeutic agents. Jugular vein cannulated Sprague-Dawley rats were randomly assigned to receive the following treatments intraduodenally (ID): [3H]cyclosporin A, [3H]ritonavir, [3H]saquinavir, or [3H]acyclovir at (120 µCi/kg) alone, with protease inhibitors (PIs), or with {Delta}G (720 µg/kg)/PI. Serial blood samples were collected, and plasma was analyzed for radioactivity. After ID administration with {Delta}G/PI, Cmax significantly (p < 0.05) increased over a range of 197 to 5700%, whereas area under the plasma concentration time curve displayed significant increases extending over a range of 123.8 to 4990.3% for the investigated drugs. {Delta}G significantly increased the in vivo oral absorption of some low bioavailable drugs in the presence of PI. This study suggests that {Delta}G-mediated tight junction modulation, combined with metabolic protection, may be used to enhance the low oral bioavailability of certain drugs when administered concurrently.


Received for publication June 24, 2004
Accepted September 15, 2004.

Address correspondence to: Dr. Natalie D. Eddington, Pharmacokinetics-Biopharmaceutics Laboratory, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Health Sciences Facility II, 20 Penn Street, Room 543, Baltimore, MD 21201. E-mail: neddingt{at}rx.umaryland.edu




This article has been cited by other articles:


Home page
IOVSHome page
J. Martin, P. Malreddy, T. Iwamoto, L. C. Freeman, H. J. Davidson, J. M. Tomich, and B. D. Schultz
NC-1059: A Channel-Forming Peptide That Modulates Drug Delivery across In Vitro Corneal Epithelium
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3337 - 3345.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Fasano
Physiological, Pathological, and Therapeutic Implications of Zonulin-Mediated Intestinal Barrier Modulation: Living Life on the Edge of the Wall
Am. J. Pathol., November 1, 2008; 173(5): 1243 - 1252.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.